SCHEMBL410767

SCHEMBL410767

OCc1cccc(-c2cc(Cl)cc(Cl)c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.56
CHKA P35790 1/20 0.56
RXRA P19793 1/20 0.50
RXRB P28702 1/20 0.50
CYP2C9 P11712 1/20 0.48
NR4A2 P43354 1/20 0.48
KCNH2 Q12809 1/20 0.48
ACMSD Q8TDX5 1/20 0.47
FYN P06241 1/20 0.46
MAP2K4 P45985 1/20 0.45
TAAR1 Q96RJ0 1/20 0.44
CNR2 P34972 1/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA7 P36544 1/20 0.44
CDK8 P49336 1/20 0.43
CNR1 P21554 1/20 0.42
MRGPRX4 Q96LA9 1/20 0.42
ENPP2 Q13822 1/20 0.42
IKBKB O14920 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6968998 0.90 PRKCI (0.58) PRKCICHKACYP2C9NR4A2KCNH2
SCHEMBL23750141 0.85 PRKCI (0.67) PRKCICYP2C9NR4A2KCNH2ACMSD
SCHEMBL4191589 0.85 PRKCI (0.72) PRKCICYP2C9NR4A2KCNH2ACMSD
SCHEMBL11147920 0.84 PRKCI (0.61) PRKCICHKACYP2C9NR4A2KCNH2
SCHEMBL18297788 0.83 PRKCI (0.76) PRKCICYP2C9ACMSDFYNMAP2K4
SCHEMBL6477595 0.82 CHKA (0.57) CHKARXRARXRBTAAR1CNR1
SCHEMBL31540766 0.81 FFAR4 (0.45) PRKCICHKARXRARXRBFYN
SCHEMBL18586418 0.80 FFAR4 (0.50) PRKCICHKARXRARXRBTAAR1
SCHEMBL12577777 0.80 MAP2K4 (0.53) PRKCICYP2C9NR4A2KCNH2ACMSD
SCHEMBL249824 0.79 PRKCI (0.70) PRKCIACMSDFYNCNR2CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112384509-A Furin inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2021-02-19 CN disclosed
EP-2325651-B1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding SCRIPPS RESEARCH INST (US) 2014-10-08 EP disclosed
EP-2325651-B1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding SCRIPPS RESEARCH INST (US) 2014-10-08 EP disclosed
US-20140134753-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2014-05-15 US disclosed
US-20140134753-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2014-05-15 US disclosed
US-20140134753-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2014-05-15 US disclosed
US-8653119-B2 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE (US) 2014-02-18 US disclosed
US-8653119-B2 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE (US) 2014-02-18 US disclosed
US-8653119-B2 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE (US) 2014-02-18 US disclosed
US-20120309835-A1 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES REVISION THERAPEUTICS, INC. (US) 2012-12-06 US disclosed
US-20070078186-A1 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE 2007-04-05 US disclosed
US-20070078186-A1 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE 2007-04-05 US disclosed
US-20070078186-A1 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE 2007-04-05 US disclosed
US-20070015827-A1 Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation SYTERA, INC. (US) 2007-01-18 US disclosed
US-20060135460-A1 Methods, assays and compositions for treating retinol-related diseases SYTERA, INC. (US) 2006-06-22 US disclosed
WO-2006063128-A2 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES SIRION THERAPEUTICS, INC. (US) 2006-06-15 WO disclosed
US-20060057644-A1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding SCRIPPS RESEARCH INSTITUTE, THE 2006-03-16 US disclosed
EP-1587821-A2 COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING The Scripps Research Institute (US) 2005-10-26 EP disclosed
US-20040152140-A1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding THE SCRIPPS RESEARCH INSTITUTE 2004-08-05 US disclosed
WO-2004056315-A2 COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING THE SCRIPPS RESEARCH INSTITUTE (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078186-A1 Methods for treating transthyretin amyloid diseases TTR, TTPA, PRNP PRKCI 2823/4885CHKA 3487/4885RXRA 3616/4885
US-20120309835-A1 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES RBP1, RBP4, TTR PRKCI 2444/4885CHKA 3388/4885RXRA 51/4885
US-20060135460-A1 Methods, assays and compositions for treating retinol-related diseases RBP1, RBP4, TTR PRKCI 2444/4885CHKA 3388/4885RXRA 51/4885
US-20070015827-A1 Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation RBP1, RBP4, ALDH1A2 PRKCI 1560/4885CHKA 2943/4885RXRA 23/4885
US-20060057644-A1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding TTR, TTPA, PRNP PRKCI 2877/4885CHKA 3796/4885RXRA 3902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.